Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.

ABSTRACT: Cannabidiol (CBD) use has increased in America due to its widespread availability. Cannabidiol is metabolized by multiple polymorphic enzymes including CYP3A, CYP2C9, and CYP2C19. We sought to evaluate the genotype-specific adverse events and pharmacokinetic profiles of cannabidiol, 7-OH cannabidiol (an active metabolite), and 7-COOH cannabidiol. We completed a secondary analysis of an open-label, fixed-sequence, single-center study of cannabidiol in 33 healthy subjects. Patients first received a single dose of cannabidiol 5 mg/kg orally with serial plasma concentrations measured. Later, patients were titrated to 5 mg/kg twice daily for 14 days to reach steady state with serial plasma concentrations measured. CYP3A, CYP2C9, and CYP2C19 genotypes were assessed. Pharmacokinetic parameters we

SUBMITTER: Etkins J 

PROVIDER: S-EPMC12741916 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature